Galectin Therapeutics Inc. (GALT )

Currency in USD Disclaimer
$1.04 -$0.96 (-48%)
Closed 12/20/2024
$0.73
$1.5
$0.73
$4.27

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol GALT
  • Company Galectin Therapeutics Inc.
  • Price $1.04
  • Changes Percentage -48
  • Change -0.96
  • Day Low $0.73
  • Day High $1.5
  • Year High $4.27
  • Year Low $0.73
  • Market Cap $64,800,424
  • Price Avg 50 EMA (D) $2.54
  • Price Avg 200 EMA (D) $2.65
  • Exchange NASDAQ
  • Volume 9,152,099
  • Average Volume 294,015
  • Open $1.18
  • Previous Close $2
  • EPS -0.73
  • PE -1.42
  • Earnings Announcement 2025-03-27 12:00:00
  • Shares Outstanding $62,308,100

Company brief: GALECTIN THERAPEUTICS INC. (GALT )

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Corporation News

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

December 20, 2024 at 1:00 pm ET

globenewswire.com -- NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its globa...

Income Statement